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Novel data analysis method for 
multicolour flow cytometry links 
variability of multiple markers on 
single cells to a clinical phenotype
Gerjen H. Tinnevelt  1,2, Marietta Kokla  1, Bart Hilvering3, Selma van Staveren2,3, Rita 
Folcarelli1, Luzheng Xue4, Andries C. Bloem5, Leo Koenderman3, Lutgarde M. C. Buydens1 & 
Jeroen J. Jansen1
Multicolour Flow Cytometry (MFC) produces multidimensional analytical data on the quantitative 
expression of multiple markers on single cells. This data contains invaluable biomedical information on 
(1) the marker expressions per cell, (2) the variation in such expression across cells, (3) the variability 
of cell marker expression across samples that (4) may vary systematically between cells collected from 
donors and patients. Current conventional and even advanced data analysis methods for MFC data 
explore only a subset of these levels. The Discriminant Analysis of MultiAspect CYtometry (DAMACY) 
we present here provides a comprehensive view on health and disease responses by integrating all four 
levels. We validate DAMACY by using three distinct datasets: in vivo response of neutrophils evoked 
by systemic endotoxin challenge, the clonal response of leukocytes in bone marrow of acute myeloid 
leukaemia (AML) patients, and the complex immune response in blood of asthmatics. DAMACY 
provided good accuracy 91–100% in the discrimination between health and disease, on par with 
literature values. Additionally, the method provides figures that give insight into the marker expression 
and cell variability for more in-depth interpretation, that can benefit both physicians and biomedical 
researchers to better diagnose and monitor diseases that are reflected by changes in blood leukocytes.
Multicolour Flow Cytometry (MFC) is a powerful analytical technology that is used to measure (co)-expression 
of multiple markers at a single cell resolution. A typical sample for MFC analysis may contain large numbers of 
cells (>10000), characterized by the binding of several fluorescently labelled antibodies that represent expression 
of specific cellular markers1. The analysis of such marker (co)-expression has been essential in unravelling system-
atic and comprehensive patterns in e.g. haematopoiesis, cellular function and disease mechanisms2.
The information in MFC data is widely used for multiple objectives, the most prominent being: identifying 
cell subpopulations using two-dimensional gating and interpreting cell populations associated with a clinical 
phenotype3. Analysis of variability at the single cell level will provide clinically relevant information. Generally, 
MFC datasets contain information on four hierarchical levels, that range from the individual markers of the cell 
to the differential expression of functionalized cells in clinical phenotypes:
 1) The multivariate (co)-expression of markers on single cells.
 2) Aggregation of cells into populations with similar marker expression.
 3) Representation of cell populations in a specific individual.
 4) Differentiation of this representation in specific clinical phenotypes.
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Several existing methods for MFC data analysis may predict accurately the phenotype a sample presents, but 
fail to quantitatively link the interplay between specific markers to e.g. disease specific cells4. Several methods 
use e.g. median fluorescence intensity or work with sequential two-dimensional gating steps to select specific 
cells. Two-dimensional multiple gating regions of interest are subjectively defined in bivariate plots, but impor-
tant information is lost during every sequential two-dimensional gating step. Therefore, these methods can be 
viewed as multiple-univariate or multiple-bivariate and miss the comprehensive link between the four levels. 
Either approach does not employ the expression of more than two markers of a single cell, such that the MFC data 
is not interpreted to its full potential.
Recently, several multivariate methods have been developed that provide a canonical view on the 
(co)-expression of all markers. Fischer Information Nonparametric Embedding (FINE)5 uses Multidimensional 
Scaling to observe variability between samples, which may be used to explore response-related patterns. However, 
the link FINE draws between marker expression and variability between individuals is non-linear, such that 
relevant connections can only be drawn from post hoc interpretation of the model results. Likewise, the ViSNE6 
approach visualizes the aggregation of cells for each individual by reducing the dimensions with a non-linear 
t-Distributed Stochastic Neighbour Embedding (t-SNE), such that the representation of single-cells (level 2) can-
not be directly linked to the multivariate co-expression of markers (level 1). Moreover, neither method allows a 
projection of an individual sample (level 3) into the multidimensional model space to evaluate their similarity 
to samples in the calibration set on which the model was fitted (level 4). Several other methods that were spe-
cifically developed for MFC data analysis, use specific representations of the cellular composition of a sample 
(level 2) to find biomarkers for a clinical phenotype. Frequency Difference Gating7 (FDG), another method uses 
probability binning to get an equal number of cells in each bin, based on those measured in the control samples 
and then identifies bins differentially expressed in a specific (clinical) phenotype. The SPADE method constructs 
Figure 1. Shows a biplot of the cells of a typical control (left) and a typical LPS-responding individual (right). 
Each dot represents a score, thus a single cell. The model loadings are represented by vectors and indicate 
how each surface marker contributes to the cell variability in a specific direction. The percentage given is the 
explained variance per PC of that individual.
Figure 2. Smoothed histograms of the biplots shown in Fig. 1 of a typical control (left) and a typical LPS-
responding individual (right). The darker bin, the more cells are likely present in that location. The same 
loadings are plotted on top as vectors and indicate how each surface marker contributes to the cell variability in 
a specific direction.
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hierarchical clusters to differentiate cell populations8 that may be associated to a specific clinical phenotype9. Also 
Citrus10 uses hierarchical clustering to find such discriminating cell populations with an alternative regression 
approach called lasso-regularized logistic regression. Although these three approaches are multivariate and lin-
ear, they fail to show how the multivariate marker (co)-expression (level 1) underlies the cell diversity (level 2). 
Interpretations of such co-expressions are limited to qualitative comparisons between the expression of single 
markers in a multiple-univariate comparison.
Another common method in flow cytometry is Principal Component Analysis (PCA), which reduces the 
dimensions in order to study the most prominent variation in (co)-expression of all markers across all cells 
exhibited by specific clinical phenotypes11, 12. Two methods, Automated Population Separator (APS)13 and Flow 
cytometric Orthogonal Orientation for Diagnosis (FLOOD)14 use PCA. The advantage of PCA is that you can 
represent the single cells together with the interrelated expressions of the markers in a biplot. The APS method 
creates a PCA model for every phenotype based on all the cells of the individuals in that phenotype. Next, a new 
measurement is projected into each PCA model and the closest clinical phenotype is selected as the predicted 
phenotype. FLOOD builds a PCA model based on the marker variability in healthy individuals and subsequently 
models the variability only observed in responding individuals. FLOOD then counts the number of responding 
cells. However, some cells may be more specific for a clinical phenotype than others. Therefore, it would be better 
to use regression to give specific cells higher weights.
In this paper we present Discriminant Analysis of MultiAspect CYtometry (DAMACY), a multivariate 
method that uses PCA biplots and multivariate regression based on Partial Least Squares (PLS) to quantitatively 
compare the leukocyte compositions of multiple individuals, specifically those correlated to the discrimination 
of individual groups based on their immune response. Thereby, DAMACY can integrate all four levels of MFC 
information and in this way, differentiate between clinical phenotypes based on quantified co-expression of mul-
tiple markers on different cell populations.
Results
We demonstrate the strength that DAMACY has to describe homeostasis and deviations in the haematological 
and immunological system by three complementary case studies. We acquired the first dataset to study the in 
vivo effect of lipopolysaccharide (LPS) on blood neutrophils. The second data set focussed on the identification 
of tumour cells within bone marrow samples of patients with acute myeloid leukaemia (AML). We obtained the 
third dataset from total leukocytes isolated from patients with different phenotypes of asthma. The control group 
in this article is stated as controls and the other group as challenged individuals.
For benchmarking against other methods, we evaluated the predictive ability of DAMACY in two Flow 
Cytometry: Critical Assessment of Population Identification Methods (FLOWCAP) II challenge datasets4. The 
99% accuracy on the AML and 100% accuracy on the HIV Vaccine Trials Network (HVTN) datasets of DAMACY 
is comparable to the other evaluated methods. We provide more details in the Supplementary material.
Lipopolysaccharide challenge. Intravenous administration of lipopolysaccharide (endotoxin) elicits a sys-
temic inflammatory response syndrome in humans (SIRS)15. Neutrophils demonstrate a characteristic difference 
in expression of CD16 and CD62L, together with a larger array of alterations in co-expressed surface markers15.
The DAMACY model on the LPS data (Fig. 1) required two Base Principal Components (PCs) to explain 
65% of the total variability across cells within all samples. Specifically, the first PC explains considerably more 
variability in challenged individuals (59%) than in controls (19%), which indicates that the Base model describes 
considerable response-specific cell variability. The score distributions show that this response entails a distinc-
tive ‘bean’ shape following a continuous gradient in marker expression (see figure right panel Fig. 2) that is not 
observed in control individuals.
Figure 3. DAMACY model of LPS data. The left panel shows the average prediction score of controls (red 
rounds) and LPS-responding individuals (blue crosses) based on the results of the double cross-validation. The 
right panel shows negative weights as red and positive weights as blue. The blue contour depicts where most 
cells of the enlarged cross are. The red contour depicts where most cells of the enlarged round are. The loadings 
of the Base model are plotted on top as black vectors and indicate how each surface marker contributes to the 
cell variability in a specific direction. The marker expression of cells near ▷, ■, + are discussed in the text.
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Qualitative comparison of both biplots show clear differences induced by LPS. The individual cell scores can 
however not be directly quantitatively compared between individuals: such comparison needs to transcend the 
single-cell level. This could be achieved by gating the cells, however the observed continuous distribution in 
marker expression prohibits setting a discrete gate. Therefore, we used a small binsize to bin the cell scores in 
order to retain as much resolution in the marker expression as possible. Supplementary Figure 1 shows the cel-
lular distribution of a typical sample in an unsmoothed histogram, which is very grainy and therefore poorly 
comparable between samples. Histogram smoothing resolves the continuous distribution that underlies these 
bins, which can be much better quantitatively compared between samples (Fig. 2).
The immune response of neutrophils to LPS, can be interpreted by quantitative comparison of these smoothed 
histograms. We performed this comparison by OLPS-DA, which leads to perfect diagnosis of the LPS-specific 
response (Fig. 3, right). The blue and red regions indicate the most discriminative bins, coloured according to 
their weight in the discriminant model, where blue bins contain a larger fraction of cells in challenged and red 
bins larger fractions in the control samples. The cross-validated prediction scores (Fig. 3, left) show the classifica-
tion of each sample as either challenged or control based on these weights.
Two benchmarks, coloured in orange and blue in Fig. 3, encircle the 80% bins most highly occupied by single 
cells. The area with the most decreasing cell fraction decreases upon LPS response (coloured most intensely red 
in Fig. 3) is also encircled by the blue benchmark, which indicates that peripheral blood of responders contains a 
considerable fraction of cells with this surface marker expression, identified as normal mature neutrophils, even 
upon response16.
Figure 4. DAMACY model of AML data. The left panel shows the average prediction score of controls (red 
rounds) and AML patients (blue crosses). The right panel shows negative weights as red and positive weights 
as blue. The loadings of the Base model are plotted on top as black vectors and indicate how each marker 
contributes to the cell variability in a specific direction.
Figure 5. DAMACY model of asthma data. The left panel shows the average prediction score of the OPLS-DA 
model of controls as red rounds and asthma individuals as blue crosses. The right panel shows negative weights 
as red and positive weights as blue. The loadings of the Base model are plotted on top as black vectors and 
indicate how each surface marker contributes to the cell variability in a specific direction within the model. The 
symbols indicate the centroid of that coloured area that are representative for different cell populations (see 
Table 1).
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The most intensively in- or decreasing bins in the leukocyte map may be subdivided into three distinct regions 
that we gated for further inspection (Supplementary Figures 2 and 3). Control samples contain a higher fraction 
of cells near ■ than responders. These cells have an average expression of all markers. Cells near + are more 
abundant in LPS responders; their expression of CD11b, CD11c, CD16 and CD69 is higher. Cells near ▷ are also 
more abundant in LPS responders, but the expression of CD11b, CD11c, CD16 and CD69, is lower than average 
while they co-express more CD62L. The elongated shape of the blue coloured bins near ▷ along the CD62L load-
ing shows that cells vary considerably in their expression of this marker. The expression of CD32 and CD64 is not 
oriented towards any specific region, and therefore does not associate with specific groups of cells responding to 
LPS. The large loading of CD32 indicates that the expression of this marker varies considerably between all neu-
trophils. The small CD64 loading shows it does not contribute to the modelled marker expressions.
The continuum in marker expression could not be observed in the bivariate plot of the most prominent surface 
markers CD62L and CD16 (Supplementary Figure 4). Rather, these two markers alone show a fully independent 
and orthogonal behaviour for all cells. However, when observing the linear relationships between all markers 
simultaneously in DAMACY, a much more gradual continuum is observed. The median fluorescence intensity of 
the cells within the three gated regions (Supplementary Figure 3) shows that considerable overlap exists in single 
marker expression between the gated regions. Thus, the multivariate marker co-expressions provide a much more 
distinctive view on the immune response to LPS than single-marker evaluation of the same data.
Acute Myeloid leukaemia. AML is characterised by an expansion of abnormal immature myeloid cells 
in both the bone marrow and peripheral blood. The cellular composition of 15 bone marrow samples was ana-
lysed by MFC using the EUROFLOW ALOT screening approach17. Nine bone marrow samples were from AML 
patients and six from individuals with absence of any leukemic clones in the bone marrow (controls).
DAMACY analysis correctly discriminated between controls and AML patients (Fig. 4) with 98% accuracy in 
a six-fold cross leave-sample-out validation with 20 iterations10, 18, 19. The haematological map (right panel) shows 
an intense red region near ▲ with cells that are underrepresented in AML patients and an intense blue region 
near □ with cells that are overrepresented in AML. The cells near ▲ have a higher expression of cMPO com-
pared to cells near □; cells in both regions are myeloid because they have average or high expression of cMPO and 
low expression of other markers. Another, less intensely blue region near ◇ contains B-cells with higher expres-
sion of CD19 and cCD79a. The T-cell populations position near ☆, with relatively high expressions of CD7 and 
sCD3. These latter populations are coloured less-intensely blue and are therefore decreasingly important in the 
observed AML. DAMACY may show specific AML responses, namely a higher amount of myeloid cells and not 
in T cells or B cells. An additional finding is the lower expression of cMPO in myeloid cells in AML individuals.
Asthma phenotypes. Asthma is a heterogeneous disease characterised by symptoms of wheezing, cough, 
breathlessness and chest tightness. Current diagnosis is based on symptoms and variable airflow limitation20. In 
the current analysis we compared 24 asthma patients to 10 healthy controls. Their blood samples were charac-
terized by eight antibodies: CD3, CD4, CD8, CD14, CD16, CD123, CD193 and CD294 (CRTH2). This surface 
marker panel specifically differentiates between asthma-associated cell types, such as eosinophils, type 2 T helper 
cells (Th2-cells), type 2 cytotoxic T cells (Tc2) and basophils. The CRTH2-antibody was included to measure the 
presence of the PGD2 receptor21–23.
Each individual measurement was centred in the Base model by median based on the whole dataset, as this led 
to highest prediction accuracy among all evaluated methods. Systematically evaluation of Top models based on all 
combinations of these Base components showed that histograms of components 1 and 3 provided 91% accuracy 
in discriminating mild/severe asthma patients versus controls.
The OPLS-DA model (Fig. 5 right panel) shows the leukocyte map. Many different coloured regions can be 
found in Fig. 5 where the centroid point is denoted with a symbol. The marker expression profiles of the areas are 
given in Table 1. In the origin are the neutrophils which is likely due to median centering with neutrophils as the 
Symbol Expression Cell type
Proportionally more 
represented in:
■ CD3+CD8−CD4++ CD4 T cell Asthma
□ CD3+CD8−CD4+ CD4 T cell Control
▲ CD3+CD4−CD8++ CD8 T cell Asthma
△ CD3+CD4−CD8+ CD8 T cell Control
♠ CD3+CD8+CD4+ Double Positive T cells Asthma
◇ CD3+CD4−CD8− Double Negative T cells Control
⌂ CD14+ Monocyte Control
▼ CD16+ Neutrophil Asthma
origin CD16med Neutrophil Control (median cell)
▽ CD16dim Neutrophil Asthma
▶ CD16dimCRTH2+ Eosinophil Asthma
☆ low expression Debris/dead Cells Control
Table 1. Expression profile of the different areas marked with symbols in Fig. 5. The expression profiles are 
checked by conventional sequential two dimensional gating.
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most common cell type. The neutrophil with average CD16 expression is more represented in controls, while the 
neutrophils with higher CD16 expression and with lower expression are more represented in asthma patients. 
This CD16 pattern was also seen in the LPS data. In asthma patients the CD3+CD4+ T cells express more CD4 
and the CD3+CD8+ T cells more CD8 compared to control individuals. Naturally, asthma patients have more 
eosinophils. Monocytes and CD4/CD8 double negative T cells on the other hand are slightly more represented 
in controls. Basophils are not correlated to any of the two groups. Th2 cells and Tc2 cells overlap with the CD4 
and CD8 cells, respectively. The leukocyte map gives, in one overview, the cell types that are more represented in 
asthma patients.
Discussion
The systematic integration of MFC data into four distinct levels (see Table 2) can be quantitatively linked together 
to improve the interpretation of comprehensive cell variability in marker co-expression. DAMACY combines 
multivariate ordination and classification of markers, cells, individuals and clinical phenotypes. The four levels 
provide adequate diagnoses in our complementary case studies and link this to individualized responses in single 
cells and in co-expression of several markers.
For example, LPS leads to emergence of cells reduced in their expression of CD62L and other cells considera-
bly reduced in CD16 expression (Fig. 3). Cells which highly express CD16 and lowly express CD62L are also high 
in expression of CD11b and CD11c, a relationship between surface marker expressions that can be directly 
interpreted from the Base loadings within the leukocyte map. These cells are absent in homeostasis and can be 
used as diagnostic for acute inflammation.
The histograms show that rather than discrete populations, the neutrophil compartment of LPS responding 
individuals contains cells with a continuum of co-expression levels of these markers that cannot be observed in 
the separate expression levels. Relative differences in expression throughout this entire continuum may be distinct 
between groups of individuals, which may not be observed in SPADE and Citrus that rely on presence of discrete 
populations/clusters. To alleviate this, SPADE and Citrus use hierarchical clustering with many clusters in order 
to model the continuum. However, too many clusters results in difficulties in interpretation, while too few clusters 
may not capture all the information present. Because DAMACY does not use clustering but PCA, the clusters 
or continuum will appear as is present in the data, with easy to interpret figures as the vector loadings show the 
relative marker expression. Individualized aspects of this expression can be visualised within the DAMACY 
framework by superimposing cell variability within an individual sample onto the leukocyte cell map. The latter 
shows that this variability indeed involves up-regulation across the entire continuum for a specific individual 
(Fig. 3). The predictive scores, finally, quantify the difference between both groups of individuals, and allow a 
robust, comprehensively statistically validated result. These results show higher percentages of cells that are 
simultaneously low in CD62L and high in CD11b are indicative of endotoxemia, although the expression of these 
markers may vary across cells. These cells form a relatively larger proportion of the neutrophil population in some 
challenged individuals than in others; clearly there is considerable heterogeneity across all four levels that may be 
interpreted by DAMACY.
Amir et al. have described that single-cell data has many non-linear relationships, which cannot be used by a 
linear method such as PCA6. Non-linear relationships do, however, not disappear in linear models, as the biplot 
representation of the cell variability in LPS shows (Figs 2 and 3) a bean-like shape due to that healthy cells have a 
high expression of both CD16 and CD62L highly, whereas cells responding to LPS either express CD16 or CD62L 
highly. These effects were also observed with FLOOD14. However, FLOOD looks for response specific cells per 
individual, while DAMACY focuses more on the ratio of specific cells between controls and challenged individ-
uals and gives a general leukocyte map for all challenged individuals. Non-linear methods such as ViSNE6 and 
FINE5 have the drawback that the quantitative view on marker co-expressions is lost from the model. Also linear 
clustering methods like SPADE8 and Citrus10 allow only qualitative interpretation of marker co-expression, either 
through similarities between heatmaps of individual markers or by plotting the histograms of the individual 
markers of a single cluster as is done in Citrus and in the non-linear binning of FDG7. These methods thus fail to 
quantitatively connect the variability in marker (co)-expression on single cells with the ratio between these cells 
between MFC samples of different phenotypes.
The clinical value of DAMACY. The information content within MFC data revealed in a quantitative model 
strongly depends on the specific choices made in collecting the data and in data processing that precedes mod-
elling. The analysed sample may consist of a relatively homogeneous cell population or can interrogate a much 
broader mixture of cells, such as the whole blood and bone marrow analysed in the asthma and AML studies pre-
sented here, respectively. The results on the FLOWCAP 2 data show how the quantitative potential of DAMACY 
is on par with the most advanced methods benchmarked in this challenge. The discriminatory Top model may 
extract the response-related information on cell variability in marker expression from the Base model histograms, 
both for a priori gated homogeneous neutrophil populations (LPS) and in peripheral blood (asthma). DAMACY 
shows to be also very informative for other sample types, like bone marrow samples from the AML study.
Diagnostic ability is however not the only, and certainly not the most challenging, issue in current MFC data 
analysis. The challenge is finding all variability in biological samples that is relevant to the studied response and 
thus disregarding all irrelevant variability. This implies that markers can be disregarded in the future leading 
to more focused experiments. The asthma dataset contains some older asthma patients outside the confidence 
interval of the age of the controls. The current model is unable to separate the variance caused by age from the 
disease and this would be possible if future experiments contain age matched controls. In that way, the method 
will minimize the variance explained caused by age and maximize the variance caused by the disease.
Cell distributions, identified by the Base model histograms, may vary greatly across individuals, and even 
systematically in aspects that do not align with the studied classification. An unsupervised PCA-based Top model 
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may be very helpful for such observations (Supplementary). In the LPS study this model reveals a dim/bright 
marker profile that varies systematically among individuals in both groups, which therefore remains enveloped 
in the OPLS-DA Top model. Also the superimposing of individual histograms (Fig. 3) may be a key advantage of 
DAMACY for this.
Conclusion
The DAMACY method can be used to objectively discriminate specific clinical phenotypes and provides a com-
pletely statistically validated model that proves insightful in a range of case studies. The method does not require 
any input on cell characteristics relevant to the experiment and is thereby unbiased to the prior knowledge of the 
researcher. The DAMACY model is able to quantitatively link individual variability in a clinical phenotype to 
specific cell populations with typical levels of marker co-expression that provide a novel, broad view on responses 
in health and immunological/haematological diseases.
Methods
Data. Subjects with asthma and normal subjects participating in the LPS challenge study gave peripheral 
blood. All data were obtained by using standardized protocols. All studies and sample collection were approved 
by the medical ethics committees of University Medical Centers Utrecht (asthma patients/UMCU) and Radboud 
University Medical Center (LPS challenge/RadboudUMC), the Netherlands. These participants gave their written 
informed consent. AML data were from bone marrow and were extracted from Anonymized flow cytometry list 
mode data sets (fcs files). These data sets were originally acquired as part of the UMCUtrecht institutional work 
up scheme for evaluation of leukaemia.
Acute myeloid leukaemia data (AML). Bone marrow samples were analysed for the presence of AML by 
MFC for diagnostical purposes using the acute leukemia orientation tube (ALOT) as described by the EuroFlow 
consortium17. The ALOT tube is a single 8-color-tube designed for the identification of an expanded population 
of immature blast like cells, including AML blasts. The 8-color panel consists of detection of CD3 (cytoplasmic 
and surface), MPO (cytoplasmic), CD79a (cytoplasmic) and the surface expression of CD19, CD34, CD45 and 
CD7. The uncompensated list mode fcs data files of bone marrow samples (100.000 stained cells) of 9 AML 
patients and 6 individuals where no haematological malignancy could be detected in the BM, were used in this 
study. The flowcytometric analyses were performed on a FACSCanto II (Becton Dickinson).
Lipopolysaccharide (LPS) challenge. In the LPS challenge dataset there are 16 individuals: 8 healthy 
controls and 8 that have undertaken the LPS challenge. Flow Cytometry measurements were performed during an 
endotoxin trial (NCT01374711; www.clinicaltrials.gov). Details regarding the Flow Cytometry experiments that 
provided the data to illustrate the method are described in the Online Supplement I; source data can be accessed 
through www.flowrepository.org ID: FR-FCM-ZZEE. This dataset has been extensively analysed in two earlier 
publications.
Asthma. The asthma dataset contains 24 asthma patients (aged 22–78, =x 57) and 10 healthy controls (aged 
25–57, =x 40) were recruited at the respiratory outpatient clinics of the Churchill Oxford University Hospital, 
UK. The study received ethical approval, and written informed consent was obtained. After inclusion patients 
filled out symptom questionnaires, sputum induction was performed, blood was taken, and patients underwent 
FeNO measurement and lung functional testing. All patients were receiving appropriate asthma treatment at the 
time of blood withdrawal. Blood cells were stained with a panel of 8 antibodies including CD3, CD4, CD8, CD14, 
CD16, CRTH2 (CD294), CD123 and CD193. After staining, red blood cells were lysed using a FACS Lysing solu-
tion (Becton Dickinson). Cells were measured on a LSR Fortessa flow cytometer (Becton Dickinson).
MFC data can be arranged into matrix =













X
X
X I
1
G
1
 of size ∑ ×= N J( )i
I
i1g
G
G1
 for analysis by DAMACY, where 
Nig is the number of cells per individual ig = 11, … I1, … 1G, … IG; g = 1, ….. G indicates the pre-defined groups of 
individuals with g = 1 representing the control group and g = 2 the patient/challenged group, with j = 1, …, J 
indicates the markers. The data of each individual can analogously be denoted as
Information level DAMACY output
(1) The multivariate (co)-expression of 
markers on single cells PCA (loadings)
(2) Aggregation of cells into 
populations with similar marker 
expression
PCA (scores)
(3) Representation of cell populations 
in a specific individual Histograms
(4) Differentiation of this 
representation in specific clinical 
phenotypes
Leukocyte map based on 
OPLS-DA weights.
Table 2. The four information levels of multidimensional flow cytometric data.
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Stage 1: Data pre-processing. Data pre-processing is used in multivariate analysis, to remove arte-
facts and thereby enhance the biologically relevant information24. First, we log-transformed the matrix X to 
Xlog = log10(X)or in the case of negative values we prior subtracted the minimum value. Then we centred the data, 
to create a common point of reference to quantify the variability in marker expression between all cells.
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where 1 is a column vector of length ∑ = Ni
I
i1g g
g
g
 and matrix Dmc holds the mean-centred data of dimensions equal 
to X.
MFC data has a specific “multiset structure”25, i.e. single cells are measured per individual. Differences in the 
number of cells measured for each individual therefore need to be taken into account to base the resulting model 
equally on all samples. To equally weight each individual in the calculation of the mean, first the individual-specific 
vector mi
T
g
 needs to be calculated, from which the overall mean mT across all individuals can be subsequently 
calculated. This mean-centring removes the ‘offset’ of the marker expression from the eventual model and puts 
focus on variability in marker expression among single cells. The multiset structure opens up the possibility for 
alternative centring approaches. For example, centring each individual using mi
T
g
or specific to one of the group 
mg
T, see supplementary.
After centring, eq. 2 scales the centred data to adjust and equalize the relative contributions in expression of 
each marker within the eventual model.
=
∑ ∑
∑
= =
=
var
I
s
D( )
(2A)
g
G
i
I
g
G
g
T mc1 1
1
g
ig
=S (S )diag (2B)T
= −X D S (2C)cs mc
1
with Xcs containing the scaled data matrix of size ∑ ×= N J( )i
I
i1g g
g
g
 and S of dimensions (J × J)a vector where the 
diagonal element contains the standard deviation of each surface marker across all cells. Note that eq. 2A calcu-
lates the mean variance of each centred set, such that the resulting standard deviation is determined by each 
sample equally.
Scaling removes any differences in the absolute variability in expression between different surface markers 
that may be caused for example by differences in quantum yield of the used dyes, or in differences in variability in 
expression between different surface markers, regardless of their bioactivity.
Like for the centring, scaling may also be performed with scaling constants specific to each individual si
T
g
 or 
specific to one of the groups sg
T, see Supplementary.
Stage 2: Base model. PCA (Principal Component Analysis). Principal Component Analysis (PCA) is the 
most widely used method for dimension reduction, that reduces the data dimensionality while retaining most of 
the variability expressed in the originally measured variables26.
PCA decomposes the pre-processed data Xcs into two matrices26 according to eq. 3.
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= +X T P E (3)base base
T
cs
where Tbase of size ∑ ×= N K( )i
I
i1g
G
G1
contains the PCA scores, k = 1, …, K indicates the Principal Components 
(PCs), Pbase of size (Kbase × J) containing the loadings and E being the residuals.
The result of the decomposition consists of single-cell scores
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,
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that express the cell variability within each individual in Tbase,1g of dimensions ×N K( )i baseg . The contribution of 
each surface marker to this variability is described in the loadings; both the scores and loadings are expressed in 
a number of Kbase Principal Components (PCs), where for MFC data < K J Nibase g. The cell variability that is 
not contained in this simplified representation is given in the model residual E. The loadings of different PCs are 
mutually orthogonal and therefore constrained as =P P Ibase base
T .
When the total number of cells Nig  differs greatly per individual, the loadings Pbase
T  will be highly biased 
towards those individuals for which most cells have been measured. To avoid this, the standard PCA model in 
eq. 3 can be slightly adjusted to account for this, see eq. 4.
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The relations between cell variability and the related expression of markers can be combined in a biplot27(see 
Fig. 2).
Histogram Construction. The scores Ti g cannot be quantitatively compared between individuals, as each indi-
vidual score relates to a single cell within only one individual. In order to describe and then compare the cellular 
distributions between individuals, we can transform each score submatrix Tbase ig into a histogram matrix Hi g of 
size ∏ = F( ),kK 1 with f = 1, …, F indicating the bins within the histograms.
We determine the bin width according to the range of the scores on every PC, according to eq. 5.
δ =
. − .
F
percentile 99 95 t percentile 0 05 t( ) ( )
(5)k
k k
where tbase,kis the vector of length ∑ = Ni
I
i1g
G
G1
that contains the base model scores for all cells, for Principal 
Component kbase. Note that the bin width is determined for all individuals simultaneously, without taking into 
account the 0.1% extreme values.
Each histogram bin will contain a different number of cells for each histogram Hi g. This is why we normalize 
each histogram by summing the area under each multidimensional distribution to 1, according to eq. 6.
=H
H
N (6)
i
i
i
g
g
g
As the number of cells that is measured per sample is most often non-informative due to the analytical MFC 
protocol. Furthermore, the histograms can be plotted together with the marker loadings from the PCA model, 
resulting in a biplot (Fig. 2). This histogram reveals the cell variability, among which discrete populations can be 
identified.
Histogram Smoothing. Both biological and instrumental variability may cause slight differences in measured 
marker intensities. This may lead to cells being placed in adjacent bins for different individuals. To reduce the 
influence of such shifts we apply a Gaussian multidimensional smoothing on every histogram28. This smooth-
ing emphasizes the relations of adjacent bins and facilitates their comparability. The binsize δk (eq. 5) and the 
degree of smoothing of this algorithm are highly related parameters, as a histogram with fewer bins requires less 
smoothing because more cells are captured by the same bin29. A number of F = 500 bins and smoothing factor 5 
provided sufficient resolution in marker expression explained by the PCA scores to be interpretable and to pro-
vide sufficient discriminatory power for Kbase = 2. We extended the histogram smoothing algorithm to Kbase > 2 
in the Supplementary.
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Stage 3: Top model. The PCA base model in eq. 3 can reveal the relations between many markers with 
respect to cell variability across many individuals. However, the clinical phenotype of each individual ig is not 
used in the Base model. We therefore subject the histograms to supervised, multivariate modelling to find those 
bins in the histogram that are most distinctive for either control or challenged individuals. We first vectorise the 
histograms, such that every histogram Hi g is rearranged into a row vector h i
T
g
 of length F Kbase. These vectors can 
then be collected in a second matrix C with dimensions ∑ ×= I F( )gG g
K
1
base . The systematic differences between 
the histograms of different groups g can be predicted by Orthogonal Partial Least Squares Discriminant Analysis 
or OPLS-DA30. The columns (bins) in matrix C with small variance (<10−6) are omitted, as these do not contrib-
ute much to the top model.
OPLS-DA uses PLS regression31 to distinguish multivariate patterns between different groups of samples. 
Compared to the more conventional PLS-DA algorithm32, an Orthogonal Signal Correction (OSC) filter removes 
all the variation across histograms that is orthogonal and therefore uncorrelated to the response30, 33. The latter are 
encoded in a binary “dummy” vector y. The OPLS-DA model is given in eq. 7:
= + +⁎C t p T P E (7)
T
o o
T
top top OPLS
where ttop contain the predictive scores of length ∑ = IgG g1 and ptop of length F* contain the corresponding load-
ings, matrices To and Po
T are respectively the scores and loadings of the space that is uncorrelated to y and are not 
further considered in this study, like the model residuals in matrix EOPLS of size ∑ ×=
⁎I F( )gG g1 .
In addition to the model results above, the OPLS-DA algorithm provides a weight-vector wtop of length F* 
that indicates per bin whether it is important for either group in y. Scores ttop indicate how well the challenged 
individuals can be distinguished from their control counterparts i1.
Leukoctye map and Prediction Score. The weight vector can be refolded into an (F × F) matrix Wtop, 
when the components Kbase = 2 in the base model. This corresponds to the original histograms Hig , forming a 
leukocyte map. This map shows which histogram bins, hence which cells, are over- or underrepresented in either 
group and can be interpreted together with the predictive scores tOPLS. Each single cell increases the individual 
score positively or negatively, when it ends up in a positively or negatively weighted bin in the leukocyte map. 
Low-weight bins do not contribute to the contrast between control and challenged individuals.
Software. Function for Matlab are available at http://www.ru.nl/science/analyticalchemistry/research/
software/.
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